Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
Related Experiment Video
Updated: Oct 3, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
K Koniaras1, A R Cuddihy, H Christopoulos
1Trescowthick Research Laboratories, Peter MacCallum Cancer Institute, A'Beckett St, Melbourne, VIC 8006 Australia.
Abstract:
Cell cycle checkpoints are surveillance mechanisms that monitor and coordinate the order and fidelity of cell cycle events. When defects in the division program of a cell are detected, checkpoints prevent the pursuant cell cycle transition through regulation of the relevant cyclin-cdk complex(es). Checkpoints that respond to DNA damage have been described for the G1, S and G2 phases of the cell cycle. The p53 tumour suppressor is a key regulator of G1/S checkpoints, and can promote cell cycle delay or apoptosis in response to DNA damage. The importance of these events to cellular physiology is highlighted by the fact that tumours, in which p53 is frequently mutated, have widespread defects in the G1/S DNA damage checkpoints and a heightened level of genomic instability. G2/M DNA damage checkpoints have been defined by yeast genetics, though the genes in this response are conserved in mammals. We show here using biochemical and physiological assays that p53 is dispensable for a DNA damage checkpoint activated in the G2 phase of the cell cycle. Moreover, upregulation of p53 through serine 20 phosphorylation, does not occur in G2. Conversely, we show that the Chk1 protein kinase is essential for the human G2 DNA damage checkpoint. Importantly, inhibition of Chk1 in p53 deficient cells greatly sensitizes them to radiation, validating the hypothesis of targeting Chk1 in rational drug design and development for anti-cancer therapies.
Insights
The p53 protein is not essential for the G2 DNA damage checkpoint. However, Chk1 kinase is crucial for this checkpoint, and inhibiting it sensitizes cancer cells to radiation, supporting its use in drug development.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Cell cycle checkpoints ensure accurate cell division and prevent transitions when errors are detected.
- DNA damage checkpoints in G1, S, and G2 phases are critical for genomic stability.
- The p53 tumor suppressor is vital for G1/S checkpoints but often mutated in cancers.
Purpose of the Study:
- To investigate the role of p53 in the G2 DNA damage checkpoint.
- To determine the essential components of the human G2 DNA damage checkpoint.
- To evaluate Chk1 inhibition as a therapeutic strategy in p53-deficient cancers.
Main Methods:
- Biochemical assays
- Physiological assays
- Analysis of p53 phosphorylation and Chk1 kinase activity
- Radiation sensitivity assays in p53-deficient cells
Main Results:
- p53 is dispensable for the G2 DNA damage checkpoint.
- p53 upregulation via serine 20 phosphorylation does not occur in G2.
- The Chk1 protein kinase is essential for the human G2 DNA damage checkpoint.
- Inhibition of Chk1 sensitizes p53-deficient cells to radiation.
Conclusions:
- The G2 DNA damage checkpoint operates independently of p53.
- Chk1 is a critical mediator of the G2 DNA damage checkpoint.
- Targeting Chk1 represents a promising strategy for anti-cancer drug development, particularly for p53-deficient tumors.
Related Concept Videos
Abnormal Proliferation
Inhibition of Cdk Activity
DNA Damage can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway

